Veracyte (VCYT) stock price, revenue, and financials

Veracyte market cap is $2.9 b, and annual revenue was $120.37 m in FY 2019

$2.9 B

VCYT Mkt cap, 15-Jan-2021

$31.1 M

Veracyte Revenue Q3, 2020
Veracyte Net income (Q3, 2020)-4.1 M
Veracyte EBIT (Q3, 2020)-4.1 M
Veracyte Cash, 30-Sept-2020345.1 M
Veracyte EV2.6 B

Veracyte Revenue

Veracyte revenue was $120.37 m in FY, 2019 which is a 30.8% year over year increase from the previous period.

Embed Graph

Veracyte Revenue Breakdown

Embed Graph

Veracyte revenue breakdown by business segment: 89.2% from Testing Revenue, 6.7% from Biopharmaceutical Revenue and 4.1% from Other

Veracyte Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

72.0m92.0m120.4m

Revenue growth, %

28%31%

Cost of goods sold

28.2m33.1m36.5m

Gross profit

43.8m58.9m83.8m

Gross profit Margin, %

61%64%70%

Sales and marketing expense

32.3m41.3m53.7m

R&D expense

13.9m14.8m14.9m

General and administrative expense

23.1m24.0m29.0m

Operating expense total

70.3m81.2m99.0m

Depreciation and amortization

1.1m1.1m1.4m

EBIT

(26.5m)(22.2m)(15.1m)

EBIT margin, %

(37%)(24%)(13%)

Interest expense

4.9m2.0m677.0k

Net Income

(31.0m)(23.0m)(12.6m)

EPS

(0.9)(0.6)(0.3)

Veracyte Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

33.9m78.0m159.3m

Accounts Receivable

12.7m13.2m19.3m

Prepaid Expenses

2.0m2.4m2.2m

Inventories

5.3m3.4m6.8m

Current Assets

53.9m97.0m187.7m

PP&E

9.7m8.9m8.9m

Goodwill

1.1m1.1m2.7m

Total Assets

78.7m120.6m275.2m

Accounts Payable

3.9m2.5m2.3m

Short-term debt

1.4m1.4m

Current Liabilities

12.0m13.1m17.5m

Long-term debt

25.2m23.9m12.2m

Total Debt

25.2m25.3m13.6m

Total Liabilities

41.4m40.9m35.8m

Common Stock

34.0k41.0k50.0k

Additional Paid-in Capital

248.3m313.8m486.1m

Retained Earnings

(211.1m)(234.1m)(246.7m)

Total Equity

37.2m79.8m239.5m

Debt to Equity Ratio

0.7 x0.3 x0.1 x

Debt to Assets Ratio

0.3 x0.2 x0 x

Financial Leverage

2.1 x1.5 x1.1 x

Veracyte Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(31.0m)(23.0m)(12.6m)

Depreciation and Amortization

3.8m3.9m4.1m

Accounts Receivable

(4.0m)(452.0k)(6.2m)

Inventories

(1.8m)1.9m(3.4m)

Accounts Payable

1.7m(1.6m)(141.0k)

Cash From Operating Activities

(23.9m)(13.5m)(3.2m)

Purchases of PP&E

(1.8m)(1.9m)(2.8m)

Cash From Investing Activities

(1.2m)(1.9m)(42.7m)

Long-term Borrowings

(25.7m)(292.0k)(25.2m)

Cash From Financing Activities

(218.0k)59.5m127.3m

Net Change in Cash

(25.3m)44.1m81.3m

Interest Paid

2.7m1.5m332.0k

Income Taxes Paid

21.0k79.0k35.0k

Veracyte Ratios

USDFY, 2017

EV/EBIT

-8.1 x

EV/CFO

-8.9 x

Revenue/Employee

292.5k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x

P/E Ratio

(7.2)

Veracyte Operating Metrics

FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020

Genomic Classifiers Reported

26.03 k6.86 k7.69 k8.01 k31.71 k9.16 k9.66 k9.94 k39.61 k10.56 k5.38 k

Genomic Tests Offered

3 3 5

Completed Clinical Studies to Date

30 38 45

Facilities

2 2 2

Veracyte Employee Rating

3.147 votes
Culture & Values
3.5
Work/Life Balance
3.9
Senior Management
3.3
Salary & Benefits
3.4
Career Opportunities
3.2
Source